Business Context and Reporting Period
This Form 8-K Current Report was filed by Quince Therapeutics, Inc. on March 1, 2023, covering events occurring on March 1 and March 3, 2023. The company is a biopharmaceutical entity incorporated in Delaware with its principal executive offices in South San Francisco, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance data.
Material Changes
The primary material change reported is the departure of a senior financial officer and the subsequent appointment of a replacement:
- Resignation: Ted Monohon resigned as Chief Accounting Officer, Vice President of Finance, Principal Financial Officer, and Principal Accounting Officer, effective March 16, 2023.
- Appointment: Brendan Hannah, previously the Chief Business Officer, was appointed as the new Principal Financial Officer and Principal Accounting Officer, effective March 16, 2023.
Management Commentary and Risks
Management stated that Mr. Monohon's resignation did not arise from any disagreement with the Company or the Board of Directors regarding operations, policies, or practices. Mr. Monohon has agreed to assist with the transition. Regarding the new appointee, Mr. Hannah will assume his new roles without any change to his existing compensation arrangement. The filing notes no family relationships between Mr. Hannah and current directors or officers, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Confirm the effective date of the leadership transition (March 16, 2023).
- Verify Mr. Hannah's prior experience in biopharmaceutical operations and strategy.
- Monitor future filings for the appointment of a new Chief Accounting Officer or Vice President of Finance, as Mr. Hannah's appointment specifically covers the principal financial and accounting officer roles.
- Review subsequent 10-Q or 10-K filings for financial metrics not included in this 8-K.